Chimeric antigen receptor (CAR)-engineered t cells redirected against hepatitis C virus (HCV) E2 glycoprotein

Gut

Volumn 65, Issue 3, 2016, Pages 512-523

  Sautto, Giuseppe A ^a   Wisskirchen, Karin ^b   Clementi, Nicola ^a   Castelli, Matteo ^a   Diotti, Roberta A ^a   Graf, Julia ^b   Clementi, Massimo ^a   Burioni, Roberto ^a   Protzer, Ulrike ^b   Mancini, Nicasio ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; GAMMA INTERFERON; GLYCOPROTEIN E2; GRANZYME B; INTERLEUKIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY E137; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; GLYCOPROTEIN E2, HEPATITIS C VIRUS; LYMPHOCYTE ANTIGEN RECEPTOR; VIRUS ENVELOPE PROTEIN;

ANTIGEN RECOGNITION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONCENTRATION RESPONSE; CROSS REACTION; CYTOKINE RELEASE; DEGRANULATION; DRUG EFFICACY; DRUG MECHANISM; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; LYMPHOCYTE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; T LYMPHOCYTE; VIRAL CLEARANCE; CELL CULTURE; CELL ENGINEERING; EVALUATION STUDY; HEPACIVIRUS; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES; VIROLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; CELL ENGINEERING; CELLS, CULTURED; HEPACIVIRUS; HEPATITIS C; HEPATOCYTES; HUMANS; IMMUNOTHERAPY; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; VIRAL ENVELOPE PROTEINS;

EID: 84960347568     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-308316     Document Type: Article

References (55)

1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011;17:107-15.
2. Sautto G, Mancini N, Solforosi L, et al. HCV proteins and immunoglobulin variable gene (IgV) subfamilies in HCV-induced type II mixed cryoglobulinemia: a concurrent pathogenetic role. Clin Dev Immunol 2012;2012:705013.
3. Sautto G, Mancini N, Clementi M, et al. Molecular signatures of hepatitis C virus (HCV)-induced type II mixed cryoglobulinemia (MCII). Viruses 2012;4:2924-44.
4. Perotti M, Ghidoli N, Altara R, et al. Hepatitis C virus (HCV)-driven stimulation of subfamily-restricted natural IgM antibodies in mixed cryoglobulinemia. Autoimmun Rev 2008;7:468-72.
5. Delemos AS, Chung RT. Hepatitis C treatment: an incipient therapeutic revolution. Trends Mol Med 2014;20:315-21.
6. Emamzadeh-Fard S, Esmaeeli S, Arefi K, et al. Mechanisms of anti-retroviral drug resistance: implications for novel drug discovery and development. Infect Disord Drug Targets 2013;13:330-6.
7. Emamzadeh-Fard S, Fard SE, SeyedAlinaghi S, et al. Adherence to anti-retroviral therapy and its determinants in HIV/AIDS patients: a review. Infect Disord Drug Targets 2012;12:346-56.
8. Castelli M, Cappelletti F, Diotti RA, et al. Peptide-based vaccinology: experimental and computational approaches to target hypervariable viruses through the fine characterization of protective epitopes recognized by monoclonal antibodies and the identification of T cell-activating peptides. Clin Dev Immunol 2013;2013:521231.
9. Hsu SH, Yeh ML, Wang SN. New insights in recurrent HCV infection after liver transplantation. Clin Dev Immunol 2013;2013:890517.
10. Sautto G, Tarr AW, Mancini N, et al. Structural and antigenic definition of hepatitis C virus E2 glycoprotein epitopes targeted by monoclonal antibodies. Clin Dev Immunol 2013;2013:450963.
11. Dubuisson J. Hepatitis C virus proteins. World J Gastroenterol 2007;13:2406-15.
12. Drummer HE, Maerz A, Poumbourios P. Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins. FEBS Lett 2003;546:385-90.
13. Tarr AW, Lafaye P, Meredith L, et al. An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission. Hepatology 2013;58:932-9.
14. Brimacombe CL, Grove J, Meredith LW, et al. Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol 2011;85:596-605.
15. Neumann-Haefelin C, Thimme R. Adaptive immune responses in hepatitis C virus infection. Curr Top Microbiol Immunol 2013;369:243-62.
16. Tarr AW, Urbanowicz RA, Ball JK. The role of humoral innate immunity in hepatitis C virus infection. Viruses 2012;4:1-27.
17. Pestka JM, Zeisel MB, Blaser E, et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci USA 2007;104:6025-30.
18. Burioni R, Mancini N, Canducci F, et al. Humoral immune response against hepatitis C virus. J Biol Regul Homeost Agents 2003;17:125-7.
19. Perotti M, Mancini N, Diotti RA, et al. Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. J Virol 2008;82:1047-52.
20. Mancini N, Diotti RA, Perotti M, et al. Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes. PLoS ONE 2009;4:e8254.
21. Diotti RA, Sautto GA, Solforosi L, et al. Neutralization activity and kinetics of two broad-range human monoclonal IgG1 derived from recombinant Fab fragments and directed against Hepatitis C virus E2 glycoprotein. New Microbiol 2012;35:475-9.
22. Sautto GA, Diotti RA, Clementi M. New therapeutic options for HCV infection in the monoclonal antibody era. New Microbiol 2012;35:387-97.
23. Burioni R, Perotti M, Mancini N, et al. Perspectives for the utilization of neutralizing human monoclonal antibodies as anti-HCV drugs. J Hepatol 2008;49:299-300.
24. Mancini N, Canducci F, Carletti S, et al. Heterogeneity of the humoral anti-HCV/E2 response in persistently infected patients as demonstrated by divergent patterns of inhibition of the binding of anti-HCV/E2 human monoclonal antibodies. J Biol Regul Homeost Agents 2003;17:183-7.
25. Sautto G, Mancini N, Diotti RA, et al. Anti-hepatitis C virus E2 (HCV/E2) glycoprotein monoclonal antibodies and neutralization interference. Antiviral Res 2012;96:82-9.
26. Nicasio M, Sautto G, Clementi N, et al. Neutralization interfering antibodies: a "novel" example of humoral immune dysfunction facilitating viral escape? Viruses 2012;4:1731-52.
27. Burioni R, Bugli F, Mancini N, et al. Nonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs. Virology 2001;288:29-35.
28. Burioni R, Matsuura Y, Mancini N, et al. Diverging effects of human recombinant anti-hepatitis C virus (HCV) antibody fragments derived from a single patient on the infectivity of a vesicular stomatitis virus/HCV pseudotype. J Virol 2002;76:11775-9.
29. Burioni R, Mancini N, Carletti S, et al. Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection. Virology 2004;327:242-8.
30. Mancini N, Carletti S, Perotti M, et al. Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment. J Med Virol 2006;78:1304-11.
31. Xiao F, Fofana I, Heydmann L, et al. Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents. PLoS Pathog 2014;10:e1004128.
32. Zhang Y, Liu Y, Moxley KM, et al. Transduction of human T cells with a novel T cell receptor confers anti-HCV reactivity. PLoS Pathog 2010;6:e1001018.
33. Chmielewski M, Hombach AA, Abken H. Antigen-specific T cell activation independently of the MHC: chimeric antigen receptor-redirected T cells. Front Immunol 2013;4:371.
34. Castelli M, Clementi N, Sautto GA, et al. HCV E2 core structures and mAbs: something is still missing. Drug Discov Today 2014;19:1964-70.
35. Bugli F, Mancini N, Kang CY, et al. Mapping B-cell epitopes of hepatitis C virus E2 glycoprotein using human monoclonal antibodies from phage display libraries. J Virol 2001;75:9986-90.
36. Plaisant P, Burioni R, Manzin A, et al. Human monoclonal recombinant Fabs specific for HCV antigens obtained by repertoire cloning in phage display combinatorial vectors. Res Virol 1997;148:165-9.
37. Burioni R, Plaisant P, Manzin A, et al. Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments. Hepatology 1998;28:810-14.
38. Solforosi L, Mancini N, Canducci F, et al. A phage display vector optimized for the generation of human antibody combinatorial libraries and the molecular cloning of monoclonal antibody fragments. New Microbiol 2012;35:289-94.
39. Engels B, Cam H, Schuler T, et al. Retroviral vectors for high-level transgene expression in T lymphocytes. Hum Gene Ther 2003;14:1155-68.
40. Krebs K, Bottinger N, Huang LR, et al. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology 2013;145:456-65.
41. Owsianka AM, Timms JM, Tarr AW, et al. Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J Virol 2006;80:8695-704.
42. Tam SP, Zhang X, Cuthbert C, et al. Effects of dimethyl sulfoxide on apolipoprotein A-I in the human hepatoma cell line, HepG2. J Lipid Res 1997;38:2090-102.
43. Mee CJ, Harris HJ, Farquhar MJ, et al. Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells. J Virol 2009;83:6211-21.
44. Davila ML, Kloss CC, Gunset G, et al. CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS ONE 2013;8:e61338.
45. Zhong XS, Matsushita M, Plotkin J, et al. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther 2010;18:413-20.
46. Hall CH, Kassel R, Tacke RS, et al. HCV+ hepatocytes induce human regulatory CD4+T cells through the production of TGF-beta. PLoS ONE 2010;5:e12154.
47. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003;197:633-42.
48. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013;10:553-62.
49. Masiero S, Del Vecchio C, Gavioli R, et al. T-cell engineering by a chimeric T cell receptor with antibody-type specificity for the HIV-1 gp120. Gene Ther 2005;12:299-310.
50. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725-33.
51. Bohne F, Chmielewski M, Ebert G, et al. T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes. Gastroenterology 2008;134:239-47.
52. Billerbeck E, de Jong Y, Dorner M, et al. Animal models for hepatitis C. Curr Top Microbiol Immunol 2013;369:49-86.
53. Vercauteren K, de Jong YP, Meuleman P. HCV animal models and liver disease. J Hepatol 2014;61:S26-33.
54. Gutti TL, Knibbe JS, Makarov E, et al. Human hepatocytes and hematolymphoid dual reconstitution in treosulfan-conditioned uPA-NOG mice. Am J Pathol 2014;184:101-9.
55. Washburn ML, Bility MT, Zhang L, et al. A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology 2011;140:1334-44.